Jan 26 (Reuters) - The U.S. Food and Drug Administration said on Thursday that AstraZeneca's COVID-19 antibody cocktail Evusheld is not currently authorized for use in the United States until further notice by the agency. (Reporting by Bhanvi Satija in Bengaluru)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,124 GBX | -0.26% | +7.26% | +14.02% |
12:52pm | Angle shares up on assay development deal with AstraZenaca | AN |
12:34pm | Angle Plc to Supply Prostate Cancer Androgen Receptor Detection Assay to AstraZeneca | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.02% | 235B | |
+29.68% | 681B | |
+19.58% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+4.34% | 199B | |
-12.02% | 189B | |
-3.79% | 157B | |
-3.34% | 149B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- U.S. FDA withdraws authorization for AstraZeneca's Evusheld